Technology: Atrificial Vectors and Immune Cells, CAR-T, CAR-T therapy, Cell_Therapies
Industry: Atrificial Vectors and Immune Cells, CAR-T, Delisted
Headquarters: Los Angeles, California, United States
Founded Date: 2009-01-01
Employees Number: 101-250
Funding Status: M&A
Investor Type: Venture Capital
Number Of Exits: 3
Acquisitions Number: Made Acquisitions, Was Acquired
Investors Number: 4
Total Funding: 285125000
Estimated Revenue: $10B+
Last Funding Date: 2015-12-10
Last Funding Type: Post-IPO Equity

Visit Website
info@kitepharma.com
https://www.twitter.com/kitepharma
Register and Claim Ownership